US2011223171A1PendingUtilityA1
Methods and Compositions for the Diagnosis and Treatment of Cyclin A-1 Associated Conditions
Individually held — no corporate assignee on recordPriority: Apr 26, 2004Filed: Mar 21, 2011Published: Sep 15, 2011
Est. expiryApr 26, 2024(expired)· nominal 20-yr term from priority
G01N 2333/9121C12N 2310/111C12N 15/113C12N 2310/14A61P 35/00G01N 33/57515
33
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to compositions and methods for cancer therapeutics. In particular, the present invention provides compositions and methods for inhibiting cancer metastasis by inhibiting cyclin A1.
Claims
exact text as granted — not AI-modified1 - 9 . (canceled)
10 . A method of modulating cyclin A1 signaling, comprising
a) providing:
i) a subject with one or more signs or symptoms of carcinoma; and
ii) a preparation comprising a cyclin A1 antagonist selected from the group consisting of 1) Six1 siRNA, 2) anti-cyclin A1 antibody, and 3) anti-Six1 antibody; and
b) administering said preparation to said subject under conditions such that the amount of cyclin A1 is modulated in said subject.
11 . (canceled)
12 . The method of claim 10 , wherein said cyclin A1 modulation is modulation in the activity of cyclin A1.
13 - 14 . (canceled)
15 . The method of claim 1 , wherein said cyclin A1 antagonist inhibits the interaction of a Six1 homeoprotein with cyclin A1.
16 . The method of claim 10 , wherein said subject has breast cancer.
17 - 20 . (canceled)
21 . The method of claim 10 , wherein said cyclin A1 antagonist comprises Six1 siRNA.
22 . The method of claim 10 , wherein said cyclin A1 antagonist comprises anti-cyclin A1 antibody.
23 . The method of claim 10 , wherein said cyclin A1 antagonist comprises anti-Six1 antibody.Join the waitlist — get patent alerts
Track US2011223171A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.